Back to search
FDAFDA · Food and drugs·Recall number Z-2332-2021

Normand Remisol Advance Data Manager, REF: C69412, C69413, C44703, and C57017 is a software device that interfaces between laboratory information systems (LIS) and laboratory instruments.

Published September 1, 2021 · Recall initiated: July 15, 2021

Summary

FDA records medical device Class II recall Z-2332-2021, published September 1, 2021 and initiated July 15, 2021. Recalling firm: Beckman Coulter Inc.; Status: Terminated; Reported quantity: 180 units; Lot: Software Version 2.0 and 2.1. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a potential that the data management system may add additional cells to the patient request which could lead to erroneous patient result.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Beckman Coulter Inc.
Distributor
Worldwide distribution - US Nationwide distribution in the states of Al, CA, FL, GA, IL, IN, MA, NC, OH, PA, TN, TX and the countries of Australia, Belgium, Canada, China, Czech Republic, France, Italy, Netherlands, New Zealand, Poland, Russia, Switzerland, Taiwan, United Kingdom, United States, Zimbabwe.
Lot
Software Version 2.0 and 2.1
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Normand Remisol Advance Data Manager, REF: C69412, C69413, C44703, and C57017 is a software device that interfaces between laboratory information systems (LIS) and laboratory instruments. recalled?

Yes. FDA published recall Z-2332-2021 on September 1, 2021. Reported hazard: There is a potential that the data management system may add additional cells to the patient request which could lead to erroneous patient result.

What should I do if I have this product?

Voluntary: Firm initiated · Letter